Paul Gineste

Masitinib, a c‐kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid‐dependent asthmatics

Marc Humbert, F. de Blay, Gilles Garcia et al. · Allergy · 2009 · 136 citations

Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: A phase 2a study

C. Paul, B. Sans, Felipe Suárez et al. · American Journal of Hematology · 2010 · 111 citations · Full text

Depression in Patients with Mastocytosis: Prevalence, Features and Effects of Masitinib Therapy

Daniela Silva Moura, Serge Sultan, Sophie Georgin‐Lavialle et al. · PLoS ONE · 2011 · 75 citations · Full text

Psychological Co-morbidities, Psychiatry, Mood Symptom +11

Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study

Jacques Tébib, Xavier Mariette, Pierre Bourgeois et al. · Arthritis Research & Therapy · 2009 · 67 citations · Full text

ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension

Séverine Vermeire, Bruce E. Sands, Herbert Tilg et al. · ˜The œLancet. Gastroenterology & hepatology · 2022 · 58 citations

Inflammation, Gastrointestinal Pharmacology, Phase 2B +6